AngioDynamics, Inc. (ANGO)
15.11
-0.01
(-0.07%)
USD |
NASDAQ |
Oct 02, 16:00
15.12
0.00 (0.00%)
After-Hours: 20:00
AngioDynamics Enterprise Value : 587.18M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 587.18M |
| October 01, 2026 | 587.60M |
| September 30, 2026 | 598.44M |
| September 29, 2026 | 607.62M |
| September 28, 2026 | 605.12M |
| September 25, 2026 | 603.03M |
| September 24, 2026 | 594.27M |
| September 23, 2026 | 603.87M |
| September 22, 2026 | 610.54M |
| September 21, 2026 | 600.11M |
| September 18, 2026 | 600.95M |
| September 17, 2026 | 598.03M |
| September 16, 2026 | 601.78M |
| September 15, 2026 | 610.95M |
| September 14, 2026 | 603.87M |
| September 11, 2026 | 593.86M |
| September 10, 2026 | 592.61M |
| September 09, 2026 | 595.94M |
| September 08, 2026 | 591.77M |
| September 04, 2026 | 590.94M |
| September 03, 2026 | 602.20M |
| September 02, 2026 | 608.45M |
| September 01, 2026 | 618.46M |
| August 31, 2026 | 629.72M |
| August 28, 2026 | 618.04M |
| Date | Value |
|---|---|
| August 27, 2026 | 615.12M |
| August 26, 2026 | 611.37M |
| August 25, 2026 | 622.21M |
| August 24, 2026 | 614.71M |
| August 21, 2026 | 613.87M |
| August 20, 2026 | 616.79M |
| August 19, 2026 | 627.22M |
| August 18, 2026 | 616.79M |
| August 17, 2026 | 610.54M |
| August 14, 2026 | 618.04M |
| August 13, 2026 | 610.12M |
| August 12, 2026 | 613.87M |
| August 11, 2026 | 613.87M |
| August 10, 2026 | 613.87M |
| August 07, 2026 | 611.37M |
| August 06, 2026 | 587.18M |
| August 05, 2026 | 584.27M |
| August 04, 2026 | 590.52M |
| August 03, 2026 | 589.69M |
| July 31, 2026 | 573.84M |
| July 30, 2026 | 573.01M |
| July 29, 2026 | 567.17M |
| July 28, 2026 | 555.08M |
| July 27, 2026 | 526.72M |
| July 24, 2026 | 523.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Boston Scientific Corp. | 73.85B |
| Penumbra, Inc. | 12.06B |
| Abbott Laboratories | 196.37B |
| Alphatec Holdings, Inc. | 2.040B |
| AtriCure, Inc. | 2.711B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.40M |
| Revenue (Quarterly) | 86.61M |
| Total Expenses (Quarterly) | 98.01M |
| EPS Diluted (Quarterly) | -0.2735 |
| Gross Profit Margin (Quarterly) | 50.87% |
| Profit Margin (Quarterly) | -13.17% |
| Earnings Yield | -5.86% |
| Normalized Earnings Yield | -3.960 |